An ambispective, observational, multi-center study of first-line Lorlatinib in patients with ALK-positive non-small cell lung cancer in Korea (Lorlatinib NIS)

ENCePP Code of conduct

No information provided.

Data sources

• Data source(s):
  Other data source
• Data sources (types):
  Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown

Procedures

No information provided.